In a case relating to use of recombinant human interferon-β (IFN-β) proteins for the treatment of viral diseases, the US Court of Appeals for the Federal Circuit ruled that a “product-by-process” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results